Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

37.13USD
12 Feb 2016
Change (% chg)

$0.79 (+2.17%)
Prev Close
$36.34
Open
$36.70
Day's High
$37.15
Day's Low
$36.40
Volume
1,676,311
Avg. Vol
1,986,579
52-wk High
$51.72
52-wk Low
$36.00

ABT.N

Chart for ABT.N

About

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The Established Pharmaceutical Products segment includes... (more)

Overall

Beta: 0.98
Market Cap(Mil.): $55,387.56
Shares Outstanding(Mil.): 1,491.72
Dividend: 0.26
Yield (%): 2.80

Financials

  ABT.N Industry Sector
P/E (TTM): 21.44 30.40 37.45
EPS (TTM): 1.73 -- --
ROI: -- 14.79 14.17
ROE: -- 15.32 14.92
Search Stocks

Fitch Places Abbotts's Ratings on Negative Watch

(The following statement was released by the rating agency) CHICAGO, February 02 (Fitch) Fitch Ratings has placed Abbott Laboratories' (Abbott) ratings on Negative Rating Watch following its announced intention to acquire Alere, Inc. (ALR). Abbott had $8.4 billion in outstanding debt at Sept. 30, 2015. A full list of Fitch's ratings actions follows at the end of this release. KEY RATING DRIVERS Sound Acquisition, Increased Leverage: Abbott plans to acquire ALR for roughly $5.8 billion cash a

02 Feb 2016

Deals of the day-Mergers and acquisitions

Feb 1 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Monday:

01 Feb 2016

Abbott Labs to buy diagnostics company Alere for $5.8 billion

Abbott Laboratories said it would buy Alere Inc for $5.8 billion to become a leader in point-of-care testing, a fast-growing market as physicians increasingly adopt rapid tests that speed up treatment.

01 Feb 2016

UPDATE 4-Abbott says to buy diagnostic test maker Alere for $5.8 bln

Feb 1 Abbott Laboratories said it would buy Alere Inc for $5.8 billion and become the leader in point-of-care diagnostic testing, a market that is growing as physicians increasingly adopt rapid tests that speed up treatment.

01 Feb 2016

BRIEF-Alk Abello expands partnership into South-East Asian growth markets

* Abbott will register and sell house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet in 7 new growth markets in SE Asia

28 Jan 2016

Market for new heart valve device could take years to build

CHICAGO Top medical device makers are investing heavily in a new way to treat leaky mitral heart valves, a serious condition affecting millions of people, but it will be at least four years before the technology reaches the U.S. market. 

02 Dec 2015

Market for new heart valve device could take years to build

CHICAGO, Dec 2 Top medical device makers are investing heavily in a new way to treat leaky mitral heart valves, a serious condition affecting millions of people, but it will be at least four years before the technology reaches the U.S. market.

02 Dec 2015

Exclusive - Abbott tangles with Indian regulators over cough syrup complaint

NEW DELHI Drugmaker Abbott Healthcare is challenging West Bengal's accusation that a sample of the company's cough syrup contained excessive levels of codeine, the second multinational to question India's regulatory testing regime in recent months.

27 Oct 2015

Exclusive: India battles big pharma over cough syrup abuse, reducing supplies

NEW DELHI Indian regulators are privately pressuring major drug firms to better police how they sell popular codeine-based cough syrups to tackle smuggling and addiction, a move that is reducing supplies of a medicine doctors say is an effective treatment. | Video

27 Oct 2015

Chilean in $13.2 mln insider trading accord with U.S. regulators

NEW YORK, Oct 23 A former board member of Chile's CFR Pharmaceuticals SA has reached a $13.2 million settlement to resolve charges by a U.S. regulator that he engaged in insider trading ahead of Abbott Laboratories' $2.9 billion acquisition of the drug company.

23 Oct 2015

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $101.82 +0.12
Pfizer Inc. (PFE.N) $29.36 +0.23
Novartis AG (NOVN.VX) CHF70.90 +1.35
Merck & Co., Inc. (MRK.N) $49.03 +0.18
Sanofi SA (SASY.PA) €68.80 +1.53
AstraZeneca plc (AZN.L) 4,046.50p +55.50
GlaxoSmithKline plc (GSK.L) 1,363.50p +18.00
Eli Lilly and Co (LLY.N) $71.27 -0.15
Amgen, Inc. (AMGN.OQ) $144.72 +3.26
Boston Scientific Corporation (BSX.N) $16.64 +0.06

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : ValuEngine, Inc.
$25.00
Provider : Stock Traders Daily
$20.00
Provider : Stock Traders Daily
$20.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks